Personal Care and Healthcare products infused with cannabidiol (CBD) are rapidly becoming the product du jour.
Derived from the hemp plant, a cousin to marijuana, CBD boasts a number of health and skin benefits because of its rich in fatty acids and natural emollients.
When applied topically, it can even help reduce oil production and therefore has been shown to have some anti-acne and anti-inflammatory characteristics. Explosive growth in the hemp-derived CBD category that has grown from a market category that did not exist five years ago to $190 Million in sales in 2017 is poised to reach a $1.0 Billion market in 2018 led by hemp-derived CBD, food, personal care and industrial products. Hemp Business Journal estimates the U.S. hemp industry will grow to a $1.9B market by 2022 giving reason more and more are jumping into this lucrative market.
Cannabis Strategic Ventures and True Promise Beauty announce the development of LYXR, a new line of cannabidiol (CBD)-based luxury skin, hair and body products. LYXR products are developed from a line of hemp-derived phytocannabinoids, and other natural ingredients that provide high-performing skin, hair and body topical solutions.
For LYXR’s inaugural product, Cannabis Strategic Ventures and True Promise Beauty have developed a facemask, which is made from a CBD isolate. CBD isolate is believed to have anti-inflammatory, analgesic, anti-oxidant properties that helps to regenerate cells, as well as, prevent the formation of bad cells (anti-cell proliferation). Additional mask proprietary ingredients will provide hydrating and anti-aging/age prevention benefits. The LYXR product line will eventually include skin, hair and body products.
“For Cannabis Strategic Ventures, LYXR represents a tremendous opportunity to marry cannabis science with an increasing global demand for luxury personal care products,” said Simon Yu, CEO, Cannabis Strategic Ventures. “More relaxed cannabis laws and an increased support for cannabis research are further legitimizing the claims surrounding CBD’s healing abilities.”
True Promise Beauty was developed by Emmy Award-Nominated Hollywood Make-Up Artist, Gail Johnson. The inspiration for True Promise Beauty was to help address the real concerns of actors and actresses working in High-Definition, where even tiny lines and wrinkles can no longer be hidden by conventional makeup and lighting techniques. True Promise Beauty products were designed to instantly smooth out fine surface lines and give a matte finish upon application leaving the user with a smoother canvas for makeup application. Through True Promise Beauty, Johnson established distribution channels with L’Oreal, Salon Centric and Beauty Systems Group. True Promise Beauty and Cannabis Strategic recently announced a joint venture agreement to develop proprietary CBD skincare line as part of Cannabis Strategic’s family of brands.
“True Promise Beauty and Cannabis Strategic Ventures will create a unique product grouping that has not previously been seen in the marketplace,” said Gail Johnson, President, True Promise Beauty, Inc. “CBD coupled with our chemists’ viable formulas will literally revolutionize the topical approach to skincare, haircare and bodycare industries. With LYXR, we are now entering a new era where we will offer products that not only provide age reversing/age preventative properties, but the scientifically proven data that CBD is at once anti-inflammatory, analgesic, anti-oxidant, cell regenerative and anti-cell proliferative.” Read this and more news for Cannabis Strategic Ventures at: http://www.marketnewsupdates.com/news/nugs.html
Other recent developments and major influences in the cannabis industry include:
MARIJUANA COMPANY OF AMERICA INC. (OTCPK:MCOA), an innovative hemp and cannabis corporation, and its joint venture partner Global Hemp Group Inc. (GHG.F) (GBHPF) recently provided an update on their CBD hemp farming joint venture in New Brunswick, Canada. Highlights include: Dryer Installation – Drying of the biomass is an important first step in the extraction of the cannabinoids from the hemp plant. The partners are pleased to announce that the Project’s industrial scale dryer from Cann Systems was delivered last week and has now been installed. >> Innovation in the Hemp Industry – It is now nearing harvest time at the New Brunswick Hemp Project. To maximize profit, it is important to harvest as much of the higher CBD content flowers and leaves as possible, without undue amounts of the low to no CBD straw (the stalk). This year’s drought has complicated matters as the hemp plants have tended to be shorter than usual, and the weeds are taller as they were able to get a head start before the hemp began growing, although the hemp is still displaying very healthy and weighty inflorescence. >> New Research Collaboration – The drought in northeast New Brunswick has not affected all fields uniformly. One of our fields is reported by DAAF field agrologists as “one of the finest of the province”. Aside from the obvious economic benefit in terms of increased yields, this field offers the opportunity to contrast high and low performing plants of a given variety in the same location, shedding some light on the role of plant nutrition in explaining the performance of hemp plants. Dr. Ron Smith from University of New Brunswick will spearhead a research project focused on the issue.
Tilray Inc. (NASDAQ:TLRY) the week announced that the U.S. Drug Enforcement Administration (DEA) has granted approval to import a cannabinoid study drug into the United States from Canada for a clinical trial at the University of California San Diego (UC San Diego) Center for Medicinal Cannabis Research (CMCR) examining its safety, tolerability and efficacy for Essential Tremor (ET). Tilray is providing a cannabinoid formulation for the trial in capsule form, which will allow researchers to test an investigational drug product containing two active ingredients extracted from the cannabis plant, cannabidiol (CBD) and tetrahydrocannabinol (THC). Dr. Fatta Nahab, a board-certified neurologist and director of the Functional Imaging of Neurodegenerative Disorders Lab at the UC San Diego Health’s Movement Disorder Center, will serve as the principal investigator for the study. It is expected to begin in early 2019 with financial support from Tilray and the International Essential Tremor Foundation.
Medical Marijuana, Inc. (OTCPK:MJNA) recently announced today that its subsidiary Kannaway® has garnered international news coverage in leading daily news publication, The Wall Street Journal. A September 12, 2018 article in The Wall Street Journal website titled “Cannabis Comes to Your Coffee and Candy-But Is It Legal?” discusses the recent popularity of cannabidiol (CBD) products around the world, highlighting the inclusion of CBD in many new food and beverage products and the complex legality of CBD in the United States. The article features commentary and cited quotes from a Kannaway® executive explaining that everyday consumers, including moms, are catching on to the popularity of CBD; and how bars and restaurants are also using CBD to enhance their menu offerings and attract more customers. “Kannaway is honored to be included of this article and the ongoing conversation surrounding CBD and its health and therapeutic benefits,” said Kannaway® CEO Blake Schroeder. “We want to continue spreading awareness of the many benefits of CBD and that people of many backgrounds can incorporate it into their everyday lives.”
CV Sciences, Inc. (OTCQB:CVSI) recently stated that the Company would like to assure our shareholders that we are keenly aware of recent market activity and certain disinformation disseminated by persons holding short positions in our stock. “As many of our shareholders are aware, our Company has been victimized by campaigns run by short sellers in order to depress our stock price, so they could make financial windfalls,” stated Joseph Dowling, Chief Executive Officer of CV Sciences. “We are also aware that at least one such group has boasted on social media platforms about its financial returns since their release of misleading information regarding the Company’s patent prosecution and drug development efforts.” Mr. Dowling continued, “While we don’t normally comment on our stock price or performance, it is important to stress that nothing has fundamentally changed in our business. We continue to deliver solid financial results, and we remain very confident in our prospects.”.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated twenty five hundred dollars for news coverage of the current press releases issued by Cannabis Strategic Ventures, Inc by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.